The drug, delivered by EMS as a single injection, improved infarct-related patency at cath lab arrival and 30-day clinical outcomes.
Hypereosinophilic syndrome (HES) is a heterogeneous disorder characterised by persistent, abnormal eosinophil elevation in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback